http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Zhiguo Wang ),( Hong Luo ),( Zehui Fang ),( Yanling Fan ),( Xiaojuan Liu ),( Yujing Zhang ),( Shuping Rui ),( Yafeng Chen ),( Luojia Hong ),( Jincheng Gao ),( Mei Zhang ) 생화학분자생물학회(구 한국생화학분자생물학회) 2018 BMB Reports Vol.51 No.9
Acute myeloid leukemia (AML) is one of the most common hematological malignancies all around the world. MicroRNAs have been determined to contribute various cancers initiation and progression, including AML. Although microRNA-204 (miR-204) exerts anti-tumor effects in several kinds of cancers, its function in AML remains unknown. In the present study, we assessed miR-204 expression in AML blood samples and cell lines. We also investigated the effects of miR-204 on cellular function of AML cells and the underlying mechanisms of the action of miR-204. Our results showed that miR-204 expression was significantly downregulated in AML tissues and cell lines. In addition, overexpression of miR-204 induced growth inhibition and apoptosis in AML cells, including AML5, HL-60, Kasumi-1 and U937 cells. Cell cycle analysis further confirmed an augmentation in theapoptotic subG1 population by miR-204 overexpression. Mechanistically, baculoviral inhibition of apoptosis protein repeat containing 6 (BIRC6) was identified as a direct target of miR-204. Enforcing miR-204 expression increased the luciferase activity and expression of BIRC6, as well as p53 and Bax expression. Moreover, restoration of BIRC6 reversed the pro-apoptotic effects of miR-204 overexpression in AML cells. Taken together, this study demonstrates that miR-204 causes AML cell apoptosis by targeting BIRC6, suggesting miR-204 may play an anti-carcinogenic role in AML and function as a novel biomarker and therapeutic target for the treatment of this disease. [BMB Reports 2018; 51(9): 444-449]
BOUNDEDNESS RESULTS FOR IMPULSIVE FUNCTIONAL DIFFERENTIAL EQUATIONS WITH INFINITE DELAYS
LI, HUA,LUO, ZHIGUO 한국전산응용수학회 2005 Journal of applied mathematics & informatics Vol.18 No.1
In this paper, boundedness criteria are established for solutions of a class of impulsive functional differential equations with infinite delays of the form $x'(t) = F(t, x(\cdot)), t > t^{\ast} {\Delta}x(t_{k})= I(t_{k}, x(t_{k}^{-})), k = 1,2,...$ By using Lyapunov functions and Razumikhin technique, some new Razumikhin-type theorems on boundedness are obtained.
Boundedness results for impulsive functional differential equations with infinite delays
Hua Li,Zhiguo Luo 한국전산응용수학회 2005 Journal of applied mathematics & informatics Vol.18 No.1-2
In this paper, boundedness criteria are established for solutions of a class of impulsive functional differential equations with infinite delays of the form x0(t) = F(t, x(·)), t>t x(tk) = I(tk, x(t−k )), k = 1, 2, ... By using Lyapunov functions and Razumikhin technique, some new Razumikhin- type theorems on boundedness are obtained.
Xin Liu,Chengcheng Gong,Jieyun Zhang,Wanjing Feng,Yanjing Guo,Youzhou Sang,Chunmeng Wang,Yong Chen,Jian Wang,Lin Yu,Xiaowei Zhang,Zhiguo Luo 대한암학회 2023 Cancer Research and Treatment Vol.55 No.3
Purpose Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal malignancy that occurs primarily in children and adolescents. The clinical and pathological features of IMT in adult patients are not well understood.Materials and Methods We retrospectively searched for records of adult patients with IMT at Fudan University Shanghai Cancer Center from 2006 to 2021. Clinicopathological data, treatments, and outcomes were collected and analyzed.Results Thirty adult patients with IMT, mostly women (60.0%), were included. The median age of the patients was 38 (21-77). The most common primary site was abdominopelvic region (53.3%), followed by lungs (20.0%). Seven patients had an abdominal epithelioid inflammatory myofibroblast sarcoma (EIMS). The positivity rate of anaplastic lymphoma kinase (ALK) was 81.5% (22/27). Sixteen patients with advanced ALK-positive disease received crizotinib, with an objective response rate (ORR) of 81.3% and a disease control rate of 87.5%. The median progression-free survival was 20.8 months. EIMS was associated with more aggressive behavior; however, the prognosis was similar to that of non-EIMS patients after treatment with an ALK inhibitor. At a median follow-up time of 30 months (95% confidence interval [CI], 13.6 to 46.4), the 5-year overall survival was 77% (95% CI, 66 to 88) in all patients.Conclusion Adult IMTs appeared more aggressive, with a higher incidence of recurrence and metastases, and patients with EIMS had more aggressive cases. Treatment with ALK inhibitors resulted in a high ORR and a durable response, which suggested that ALK inhibitors could be used as a first-line treatment option in adult patients with ALK-positive advanced IMT.